Promjene
Na 26. juni 2026., 15:36:25 UTC,
-
Nijedno polje nije ažurirano. Za više pojedinosti pogledajte promjenu metapodataka.
| f | 1 | { | f | 1 | { |
| 2 | "author": "Pure Ketamine Crystals", | 2 | "author": "Pure Ketamine Crystals", | ||
| 3 | "author_email": "inquiries.lyfeunit@proton.me", | 3 | "author_email": "inquiries.lyfeunit@proton.me", | ||
| 4 | "creator_user_id": "5ecc116b-5ec4-48f4-8366-afe5052790b1", | 4 | "creator_user_id": "5ecc116b-5ec4-48f4-8366-afe5052790b1", | ||
| 5 | "extras": [], | 5 | "extras": [], | ||
| 6 | "groups": [], | 6 | "groups": [], | ||
| 7 | "id": "9d87f30b-dd20-4df5-ad31-64a5ad68565f", | 7 | "id": "9d87f30b-dd20-4df5-ad31-64a5ad68565f", | ||
| 8 | "isopen": true, | 8 | "isopen": true, | ||
| 9 | "license_id": "other-at", | 9 | "license_id": "other-at", | ||
| 10 | "license_title": "Annan (Attribution)", | 10 | "license_title": "Annan (Attribution)", | ||
| 11 | "maintainer": "", | 11 | "maintainer": "", | ||
| 12 | "maintainer_email": "", | 12 | "maintainer_email": "", | ||
| 13 | "metadata_created": "2026-06-26T15:31:16.449902", | 13 | "metadata_created": "2026-06-26T15:31:16.449902", | ||
| n | 14 | "metadata_modified": "2026-06-26T15:36:24.954314", | n | 14 | "metadata_modified": "2026-06-26T15:36:25.132930", |
| 15 | "name": | 15 | "name": | ||
| 16 | e-ketamine-crystals-99-9-purity-cas-1867-66-9-clinical-research-data", | 16 | e-ketamine-crystals-99-9-purity-cas-1867-66-9-clinical-research-data", | ||
| 17 | "notes": "## Pure Ketamine Crystals 99.9% Purity (CAS 1867-66-9) | 17 | "notes": "## Pure Ketamine Crystals 99.9% Purity (CAS 1867-66-9) | ||
| 18 | Clinical Data\r\nThis dataset details the technical specifications and | 18 | Clinical Data\r\nThis dataset details the technical specifications and | ||
| 19 | research applications of Pure Ketamine Crystals, a laboratory-refined | 19 | research applications of Pure Ketamine Crystals, a laboratory-refined | ||
| 20 | Pharmaceutical Grade crystalline salt with a verified 99.9% purity | 20 | Pharmaceutical Grade crystalline salt with a verified 99.9% purity | ||
| 21 | level. It is optimized for high-precision pharmacological studies, | 21 | level. It is optimized for high-precision pharmacological studies, | ||
| 22 | veterinary compounding, and clinical research within the NIASRA and | 22 | veterinary compounding, and clinical research within the NIASRA and | ||
| 23 | University of Wollongong (UOW) research ecosystems.\r\n\r\nTechnical | 23 | University of Wollongong (UOW) research ecosystems.\r\n\r\nTechnical | ||
| 24 | Specifications\r\n\t\u2022\tChemical Name: | 24 | Specifications\r\n\t\u2022\tChemical Name: | ||
| 25 | 2-(2-Chlorophenyl)-2-(methylamino)cyclohexan-1-one | 25 | 2-(2-Chlorophenyl)-2-(methylamino)cyclohexan-1-one | ||
| 26 | hydrochloride\r\n\t\u2022\tCAS Number: 1867-66-9\r\n\t\u2022\tPurity: | 26 | hydrochloride\r\n\t\u2022\tCAS Number: 1867-66-9\r\n\t\u2022\tPurity: | ||
| 27 | \u2265 99.9% (HPLC Verified)\r\n\t\u2022\tAppearance: Bright white | 27 | \u2265 99.9% (HPLC Verified)\r\n\t\u2022\tAppearance: Bright white | ||
| 28 | crystalline salt\r\n\t\u2022\tSolubility: Highly soluble in water (200 | 28 | crystalline salt\r\n\t\u2022\tSolubility: Highly soluble in water (200 | ||
| 29 | mg/mL)\r\n\t\u2022\tMelting Point: 262\u00b0C to | 29 | mg/mL)\r\n\t\u2022\tMelting Point: 262\u00b0C to | ||
| 30 | 263\u00b0C\r\n\r\nResearch & Clinical | 30 | 263\u00b0C\r\n\r\nResearch & Clinical | ||
| 31 | Applications\r\n\t\u2022\tPrecision Pharmacology: Analyzing molecular | 31 | Applications\r\n\t\u2022\tPrecision Pharmacology: Analyzing molecular | ||
| 32 | integrity and NMDA receptor antagonism.\r\n\t\u2022\tVeterinary | 32 | integrity and NMDA receptor antagonism.\r\n\t\u2022\tVeterinary | ||
| 33 | Medicine: Custom concentrations for large animal sedation and | 33 | Medicine: Custom concentrations for large animal sedation and | ||
| 34 | veterinary compounding.\r\n\t\u2022\tNeuroplasticity Studies: | 34 | veterinary compounding.\r\n\t\u2022\tNeuroplasticity Studies: | ||
| 35 | Investigating long-term effects on neural pathways and psychiatric | 35 | Investigating long-term effects on neural pathways and psychiatric | ||
| 36 | interventions.\r\n\t\u2022\tStability Testing: Utilizing the 3\u20135 | 36 | interventions.\r\n\t\u2022\tStability Testing: Utilizing the 3\u20135 | ||
| 37 | year shelf life for longitudinal research projects.\r\n\r\nHandling & | 37 | year shelf life for longitudinal research projects.\r\n\r\nHandling & | ||
| 38 | Storage\r\n\t\u2022\tSafety: Utilize medical-grade PPE and work within | 38 | Storage\r\n\t\u2022\tSafety: Utilize medical-grade PPE and work within | ||
| 39 | a laminar flow hood to maintain 99.9% purity.\r\n\t\u2022\tStorage: | 39 | a laminar flow hood to maintain 99.9% purity.\r\n\t\u2022\tStorage: | ||
| 40 | Store in a cool, dry place (20\u00b0C to 25\u00b0C) in original | 40 | Store in a cool, dry place (20\u00b0C to 25\u00b0C) in original | ||
| 41 | vacuum-sealed packaging.\r\n\t\u2022\tPotency: Product remains stable | 41 | vacuum-sealed packaging.\r\n\t\u2022\tPotency: Product remains stable | ||
| 42 | for up to 5 years when protected from direct UV | 42 | for up to 5 years when protected from direct UV | ||
| 43 | exposure.\r\n\r\nSource Information\r\nFor comprehensive technical | 43 | exposure.\r\n\r\nSource Information\r\nFor comprehensive technical | ||
| 44 | data and professional procurement, | 44 | data and professional procurement, | ||
| 45 | visit:\r\nhttps://lyfeunit.com/product/buy-pure-ketamine-crystals/", | 45 | visit:\r\nhttps://lyfeunit.com/product/buy-pure-ketamine-crystals/", | ||
| 46 | "num_resources": 2, | 46 | "num_resources": 2, | ||
| 47 | "num_tags": 14, | 47 | "num_tags": 14, | ||
| 48 | "organization": null, | 48 | "organization": null, | ||
| 49 | "owner_org": null, | 49 | "owner_org": null, | ||
| 50 | "private": false, | 50 | "private": false, | ||
| 51 | "relationships_as_object": [], | 51 | "relationships_as_object": [], | ||
| 52 | "relationships_as_subject": [], | 52 | "relationships_as_subject": [], | ||
| 53 | "resources": [ | 53 | "resources": [ | ||
| 54 | { | 54 | { | ||
| 55 | "cache_last_updated": null, | 55 | "cache_last_updated": null, | ||
| 56 | "cache_url": null, | 56 | "cache_url": null, | ||
| 57 | "created": "2026-06-26T15:31:51.629634", | 57 | "created": "2026-06-26T15:31:51.629634", | ||
| 58 | "datastore_active": false, | 58 | "datastore_active": false, | ||
| 59 | "description": "", | 59 | "description": "", | ||
| 60 | "format": "", | 60 | "format": "", | ||
| 61 | "hash": "", | 61 | "hash": "", | ||
| 62 | "id": "1ad5ceec-7d75-4464-89bf-405ef1b9e75e", | 62 | "id": "1ad5ceec-7d75-4464-89bf-405ef1b9e75e", | ||
| 63 | "last_modified": null, | 63 | "last_modified": null, | ||
| 64 | "metadata_modified": "2026-06-26T15:36:24.961222", | 64 | "metadata_modified": "2026-06-26T15:36:24.961222", | ||
| 65 | "mimetype": null, | 65 | "mimetype": null, | ||
| 66 | "mimetype_inner": null, | 66 | "mimetype_inner": null, | ||
| 67 | "name": "", | 67 | "name": "", | ||
| 68 | "package_id": "9d87f30b-dd20-4df5-ad31-64a5ad68565f", | 68 | "package_id": "9d87f30b-dd20-4df5-ad31-64a5ad68565f", | ||
| 69 | "position": 0, | 69 | "position": 0, | ||
| 70 | "resource_type": null, | 70 | "resource_type": null, | ||
| 71 | "size": null, | 71 | "size": null, | ||
| 72 | "state": "active", | 72 | "state": "active", | ||
| 73 | "url": | 73 | "url": | ||
| 74 | loads/2020/10/Buy-Ketamin-Crystrals-Lydeunit-e1601799741861.jpg.webp", | 74 | loads/2020/10/Buy-Ketamin-Crystrals-Lydeunit-e1601799741861.jpg.webp", | ||
| 75 | "url_type": "" | 75 | "url_type": "" | ||
| 76 | }, | 76 | }, | ||
| 77 | { | 77 | { | ||
| 78 | "cache_last_updated": null, | 78 | "cache_last_updated": null, | ||
| 79 | "cache_url": null, | 79 | "cache_url": null, | ||
| 80 | "created": "2026-06-26T15:36:24.980870", | 80 | "created": "2026-06-26T15:36:24.980870", | ||
| 81 | "datastore_active": false, | 81 | "datastore_active": false, | ||
| 82 | "description": "This dataset provides a comprehensive technical | 82 | "description": "This dataset provides a comprehensive technical | ||
| 83 | and clinical profile of Pure Ketamine Crystals (CAS 1867-66-9). With a | 83 | and clinical profile of Pure Ketamine Crystals (CAS 1867-66-9). With a | ||
| 84 | laboratory-verified purity of 99.9%, these crystals represent the | 84 | laboratory-verified purity of 99.9%, these crystals represent the | ||
| 85 | pharmaceutical \u201cGold Standard\u201d for high-precision research. | 85 | pharmaceutical \u201cGold Standard\u201d for high-precision research. | ||
| 86 | The dataset is specifically structured to support the analytical and | 86 | The dataset is specifically structured to support the analytical and | ||
| 87 | statistical research needs of the National Institute for Applied | 87 | statistical research needs of the National Institute for Applied | ||
| 88 | Statistics Research Australia (NIASRA) and the University of | 88 | Statistics Research Australia (NIASRA) and the University of | ||
| 89 | Wollongong (UOW).\r\n\r\nChemical & Physical | 89 | Wollongong (UOW).\r\n\r\nChemical & Physical | ||
| 90 | Profile\r\n\t\u2022\tIUPAC Name: | 90 | Profile\r\n\t\u2022\tIUPAC Name: | ||
| 91 | 2-(2-Chlorophenyl)-2-(methylamino)cyclohexan-1-one | 91 | 2-(2-Chlorophenyl)-2-(methylamino)cyclohexan-1-one | ||
| 92 | hydrochloride\r\n\t\u2022\tPurity Level: \u2265 99.9% (HPLC & GC/MS | 92 | hydrochloride\r\n\t\u2022\tPurity Level: \u2265 99.9% (HPLC & GC/MS | ||
| 93 | Verified)\r\n\t\u2022\tMolecular Integrity: Optimized crystalline salt | 93 | Verified)\r\n\t\u2022\tMolecular Integrity: Optimized crystalline salt | ||
| 94 | formation for maximum bioavailability.\r\n\t\u2022\tSolubility: 200 | 94 | formation for maximum bioavailability.\r\n\t\u2022\tSolubility: 200 | ||
| 95 | mg/mL in water and physiological saline.\r\n\r\nResearch | 95 | mg/mL in water and physiological saline.\r\n\r\nResearch | ||
| 96 | Significance\r\nThe data supports advanced investigations | 96 | Significance\r\nThe data supports advanced investigations | ||
| 97 | into:\r\n\r\n\t\u2022\tDissociative Anesthesia: Benchmarking molecular | 97 | into:\r\n\r\n\t\u2022\tDissociative Anesthesia: Benchmarking molecular | ||
| 98 | purity against clinical efficacy.\r\n\t\u2022\tVeterinary Compounding: | 98 | purity against clinical efficacy.\r\n\t\u2022\tVeterinary Compounding: | ||
| 99 | Providing data for custom concentration formulations in large animal | 99 | Providing data for custom concentration formulations in large animal | ||
| 100 | sedation.\r\n\t\u2022\tLongitudinal Stability: Documenting the | 100 | sedation.\r\n\t\u2022\tLongitudinal Stability: Documenting the | ||
| 101 | 3\u20135 year shelf-life performance of crystalline salts versus | 101 | 3\u20135 year shelf-life performance of crystalline salts versus | ||
| 102 | liquid variants.\r\n\r\nInstitutional Context\r\nBy hosting this | 102 | liquid variants.\r\n\r\nInstitutional Context\r\nBy hosting this | ||
| 103 | dataset on the NIASRA/UOW portal, researchers gain access to a | 103 | dataset on the NIASRA/UOW portal, researchers gain access to a | ||
| 104 | standardized reference for pharmaceutical-grade Ketamine HCl, ensuring | 104 | standardized reference for pharmaceutical-grade Ketamine HCl, ensuring | ||
| 105 | data integrity and reproducibility in Australian clinical and | 105 | data integrity and reproducibility in Australian clinical and | ||
| 106 | laboratory environments.\r\n\r\n\r\nReference Source: Lyfeunit Pure | 106 | laboratory environments.\r\n\r\n\r\nReference Source: Lyfeunit Pure | ||
| 107 | Ketamine Crystals | 107 | Ketamine Crystals | ||
| 108 | https://lyfeunit.com/product/buy-pure-ketamine-crystals/\r\nPortal: | 108 | https://lyfeunit.com/product/buy-pure-ketamine-crystals/\r\nPortal: | ||
| 109 | NIASRA/UOW CKAN https://hpc.niasra.uow.edu.au/ckan/sv/dataset/", | 109 | NIASRA/UOW CKAN https://hpc.niasra.uow.edu.au/ckan/sv/dataset/", | ||
| 110 | "format": "", | 110 | "format": "", | ||
| 111 | "hash": "", | 111 | "hash": "", | ||
| 112 | "id": "514a1d93-4dd3-48a2-a5f3-409ceabb1069", | 112 | "id": "514a1d93-4dd3-48a2-a5f3-409ceabb1069", | ||
| 113 | "last_modified": "2026-06-26T15:36:24.948215", | 113 | "last_modified": "2026-06-26T15:36:24.948215", | ||
| n | 114 | "metadata_modified": "2026-06-26T15:36:24.961456", | n | 114 | "metadata_modified": "2026-06-26T15:36:25.136258", |
| 115 | "mimetype": null, | 115 | "mimetype": null, | ||
| 116 | "mimetype_inner": null, | 116 | "mimetype_inner": null, | ||
| 117 | "name": "Pure Ketamine Crystals 99.9 Purity Cas-1867-66-9 | 117 | "name": "Pure Ketamine Crystals 99.9 Purity Cas-1867-66-9 | ||
| 118 | Clinical-Research-Data", | 118 | Clinical-Research-Data", | ||
| 119 | "package_id": "9d87f30b-dd20-4df5-ad31-64a5ad68565f", | 119 | "package_id": "9d87f30b-dd20-4df5-ad31-64a5ad68565f", | ||
| 120 | "position": 1, | 120 | "position": 1, | ||
| 121 | "resource_type": null, | 121 | "resource_type": null, | ||
| 122 | "size": 43542, | 122 | "size": 43542, | ||
| 123 | "state": "active", | 123 | "state": "active", | ||
| 124 | "url": | 124 | "url": | ||
| 125 | 1069/download/buy-ketamin-crystrals-lydeunit-e1601799741861.jpg.webp", | 125 | 1069/download/buy-ketamin-crystrals-lydeunit-e1601799741861.jpg.webp", | ||
| 126 | "url_type": "upload" | 126 | "url_type": "upload" | ||
| 127 | } | 127 | } | ||
| 128 | ], | 128 | ], | ||
| t | 129 | "state": "draft", | t | 129 | "state": "active", |
| 130 | "tags": [ | 130 | "tags": [ | ||
| 131 | { | 131 | { | ||
| 132 | "display_name": "BP Standards", | 132 | "display_name": "BP Standards", | ||
| 133 | "id": "70157e4f-3f34-45a5-a15d-83366083f1b1", | 133 | "id": "70157e4f-3f34-45a5-a15d-83366083f1b1", | ||
| 134 | "name": "BP Standards", | 134 | "name": "BP Standards", | ||
| 135 | "state": "active", | 135 | "state": "active", | ||
| 136 | "vocabulary_id": null | 136 | "vocabulary_id": null | ||
| 137 | }, | 137 | }, | ||
| 138 | { | 138 | { | ||
| 139 | "display_name": "CAS 1867-66-9", | 139 | "display_name": "CAS 1867-66-9", | ||
| 140 | "id": "65e9d7bb-2917-42c6-a6e5-363a9c0c7b0c", | 140 | "id": "65e9d7bb-2917-42c6-a6e5-363a9c0c7b0c", | ||
| 141 | "name": "CAS 1867-66-9", | 141 | "name": "CAS 1867-66-9", | ||
| 142 | "state": "active", | 142 | "state": "active", | ||
| 143 | "vocabulary_id": null | 143 | "vocabulary_id": null | ||
| 144 | }, | 144 | }, | ||
| 145 | { | 145 | { | ||
| 146 | "display_name": "Clinical Research", | 146 | "display_name": "Clinical Research", | ||
| 147 | "id": "149201be-0dad-44d4-a36f-b2ce2be3fd6d", | 147 | "id": "149201be-0dad-44d4-a36f-b2ce2be3fd6d", | ||
| 148 | "name": "Clinical Research", | 148 | "name": "Clinical Research", | ||
| 149 | "state": "active", | 149 | "state": "active", | ||
| 150 | "vocabulary_id": null | 150 | "vocabulary_id": null | ||
| 151 | }, | 151 | }, | ||
| 152 | { | 152 | { | ||
| 153 | "display_name": "Data", | 153 | "display_name": "Data", | ||
| 154 | "id": "e0872c47-a8dc-4845-9d19-7cf661eb6120", | 154 | "id": "e0872c47-a8dc-4845-9d19-7cf661eb6120", | ||
| 155 | "name": "Data", | 155 | "name": "Data", | ||
| 156 | "state": "active", | 156 | "state": "active", | ||
| 157 | "vocabulary_id": null | 157 | "vocabulary_id": null | ||
| 158 | }, | 158 | }, | ||
| 159 | { | 159 | { | ||
| 160 | "display_name": "HPLC Verified", | 160 | "display_name": "HPLC Verified", | ||
| 161 | "id": "950b000e-6aa9-4281-9b0d-fdbb5de15342", | 161 | "id": "950b000e-6aa9-4281-9b0d-fdbb5de15342", | ||
| 162 | "name": "HPLC Verified", | 162 | "name": "HPLC Verified", | ||
| 163 | "state": "active", | 163 | "state": "active", | ||
| 164 | "vocabulary_id": null | 164 | "vocabulary_id": null | ||
| 165 | }, | 165 | }, | ||
| 166 | { | 166 | { | ||
| 167 | "display_name": "Ketamine Crystals", | 167 | "display_name": "Ketamine Crystals", | ||
| 168 | "id": "798d58a3-6fc8-415c-a6fd-19e11e49002f", | 168 | "id": "798d58a3-6fc8-415c-a6fd-19e11e49002f", | ||
| 169 | "name": "Ketamine Crystals", | 169 | "name": "Ketamine Crystals", | ||
| 170 | "state": "active", | 170 | "state": "active", | ||
| 171 | "vocabulary_id": null | 171 | "vocabulary_id": null | ||
| 172 | }, | 172 | }, | ||
| 173 | { | 173 | { | ||
| 174 | "display_name": "NIASRA", | 174 | "display_name": "NIASRA", | ||
| 175 | "id": "1b4af2e3-493f-4ee9-bfbc-30d31a49f0bf", | 175 | "id": "1b4af2e3-493f-4ee9-bfbc-30d31a49f0bf", | ||
| 176 | "name": "NIASRA", | 176 | "name": "NIASRA", | ||
| 177 | "state": "active", | 177 | "state": "active", | ||
| 178 | "vocabulary_id": null | 178 | "vocabulary_id": null | ||
| 179 | }, | 179 | }, | ||
| 180 | { | 180 | { | ||
| 181 | "display_name": "NMDA Antagonist", | 181 | "display_name": "NMDA Antagonist", | ||
| 182 | "id": "a63f032f-29d9-4d47-9122-7161fecfb948", | 182 | "id": "a63f032f-29d9-4d47-9122-7161fecfb948", | ||
| 183 | "name": "NMDA Antagonist", | 183 | "name": "NMDA Antagonist", | ||
| 184 | "state": "active", | 184 | "state": "active", | ||
| 185 | "vocabulary_id": null | 185 | "vocabulary_id": null | ||
| 186 | }, | 186 | }, | ||
| 187 | { | 187 | { | ||
| 188 | "display_name": "Pharmaceutical Grade", | 188 | "display_name": "Pharmaceutical Grade", | ||
| 189 | "id": "184bad88-3411-45d7-957e-11a377623017", | 189 | "id": "184bad88-3411-45d7-957e-11a377623017", | ||
| 190 | "name": "Pharmaceutical Grade", | 190 | "name": "Pharmaceutical Grade", | ||
| 191 | "state": "active", | 191 | "state": "active", | ||
| 192 | "vocabulary_id": null | 192 | "vocabulary_id": null | ||
| 193 | }, | 193 | }, | ||
| 194 | { | 194 | { | ||
| 195 | "display_name": "Pharmacology", | 195 | "display_name": "Pharmacology", | ||
| 196 | "id": "7b8a5e22-8b54-44a8-97e6-0fb830dde386", | 196 | "id": "7b8a5e22-8b54-44a8-97e6-0fb830dde386", | ||
| 197 | "name": "Pharmacology", | 197 | "name": "Pharmacology", | ||
| 198 | "state": "active", | 198 | "state": "active", | ||
| 199 | "vocabulary_id": null | 199 | "vocabulary_id": null | ||
| 200 | }, | 200 | }, | ||
| 201 | { | 201 | { | ||
| 202 | "display_name": "Pure Ketamine", | 202 | "display_name": "Pure Ketamine", | ||
| 203 | "id": "16b951c6-fd5b-40b4-8dfd-b918a76c776e", | 203 | "id": "16b951c6-fd5b-40b4-8dfd-b918a76c776e", | ||
| 204 | "name": "Pure Ketamine", | 204 | "name": "Pure Ketamine", | ||
| 205 | "state": "active", | 205 | "state": "active", | ||
| 206 | "vocabulary_id": null | 206 | "vocabulary_id": null | ||
| 207 | }, | 207 | }, | ||
| 208 | { | 208 | { | ||
| 209 | "display_name": "UOW", | 209 | "display_name": "UOW", | ||
| 210 | "id": "db7fb5f3-4f8e-45eb-ac60-18d37318f122", | 210 | "id": "db7fb5f3-4f8e-45eb-ac60-18d37318f122", | ||
| 211 | "name": "UOW", | 211 | "name": "UOW", | ||
| 212 | "state": "active", | 212 | "state": "active", | ||
| 213 | "vocabulary_id": null | 213 | "vocabulary_id": null | ||
| 214 | }, | 214 | }, | ||
| 215 | { | 215 | { | ||
| 216 | "display_name": "USP Grade", | 216 | "display_name": "USP Grade", | ||
| 217 | "id": "a6ff46c0-e9d0-4a0a-a2e1-029ff59797a4", | 217 | "id": "a6ff46c0-e9d0-4a0a-a2e1-029ff59797a4", | ||
| 218 | "name": "USP Grade", | 218 | "name": "USP Grade", | ||
| 219 | "state": "active", | 219 | "state": "active", | ||
| 220 | "vocabulary_id": null | 220 | "vocabulary_id": null | ||
| 221 | }, | 221 | }, | ||
| 222 | { | 222 | { | ||
| 223 | "display_name": "Veterinary Compounding", | 223 | "display_name": "Veterinary Compounding", | ||
| 224 | "id": "f9deba9c-4404-43b4-8da4-f8057f4de129", | 224 | "id": "f9deba9c-4404-43b4-8da4-f8057f4de129", | ||
| 225 | "name": "Veterinary Compounding", | 225 | "name": "Veterinary Compounding", | ||
| 226 | "state": "active", | 226 | "state": "active", | ||
| 227 | "vocabulary_id": null | 227 | "vocabulary_id": null | ||
| 228 | } | 228 | } | ||
| 229 | ], | 229 | ], | ||
| 230 | "title": "Pure Ketamine Crystals 99.9% Purity (CAS 1867-66-9) for | 230 | "title": "Pure Ketamine Crystals 99.9% Purity (CAS 1867-66-9) for | ||
| 231 | Clinical Research & Veterinary Compounding", | 231 | Clinical Research & Veterinary Compounding", | ||
| 232 | "type": "dataset", | 232 | "type": "dataset", | ||
| 233 | "url": "https://lyfeunit.com/product/buy-pure-ketamine-crystals/", | 233 | "url": "https://lyfeunit.com/product/buy-pure-ketamine-crystals/", | ||
| 234 | "version": "1.0" | 234 | "version": "1.0" | ||
| 235 | } | 235 | } |